Hydration Pharmaceuticals Company Limited · ASX:HPC
Hydration Pharmaceuticals — The Hydration Pharmaceuticals Company — Investor Presentation (November 2026)
18 slides from Hydration Pharmaceuticals's investor presentation, November 2026
Slide 1: Operational restructuring and Q3 trading update
HPC | Operational restructuring and Q3 trading update Investor presentation • November 2026 Investor Presentation rsonal use only November 2026 Improving operating performance. More efficient operations. Not for release to US wire services or distribution in the United States Funding the next phase.
Slide 2: Important information
Important information Important investor information | ASX: HPC rsonal use only Purpose and offer documents This presentation is general information only. It has been prepared by The Hydration Pharmaceuticals Company Limited (ACN 620 385 677) (HPC) in connection with its non-renounceable entitlement
Slide 3: Important information (continued)
Important information (continued) Important investor information | ASX: HPC rsonal use only Offer under the prospectus The entitlement offer is made under the prospectus dated 23 October 2026, lodged with ASIC and available on the ASX announcem ents platform and at www.hydralyte.com. Anyone who want
Slide 4: About Hydralyte USA
About Hydralyte USA A wholesale supplier and online retailer of Hydralyte hydration products in the United States rsonal use only Products Hydralyte Plus range, including Liver Support, Brain Support, Metabolic Support, Collagen Support and Immunity Support. Channels Wholesale to US retailers throug
Slide 5: Hydralyte LLC: Q3 operating loss reduced 85%
Hydralyte LLC: Q3 operating loss reduced 85% September quarter results show the impact of the operating cost reset rsonal use only 85% US$4.3k 65.1% Reduction in quarterly First monthly operating profit Q3 2026 LLC gross margin operating loss — August 2026 US$446.5k (Q3 2025) to US$66.9k (Q3 2026) O
Slide 6: September quarter: US operating turnaround
September quarter: US operating turnaround Hydralyte LLC | Q3 CY25 vs Q3 CY26 | US$000 unless stated | unaudited rsonal use only Metric Q3 CY25 Q3 CY26 Change Revenue 851.5 665.2 -21.9% Gross margin 65.8% 65.1% -0.7 ppt Advertising & marketing 373.5 170.6 54% lower Total operating expenses 746.4 313
Slide 7: September trading: stock-out impact and cash
September trading: stock-out impact and cash Hydralyte LLC monthly results and consolidated cash flow | US$000 unless stated rsonal use only Metric July 2026 August 2026 September 2026 Revenue 277.8 234.0 153.5 Gross margin 65.9% 73.3% 49.7% Operating profit / (loss) (11.4) 4.3 (59.8) Net profit / (
Slide 8: Lower marketing spend and higher revenue per marketing dollar
Lower marketing spend and higher revenue per marketing dollar Q3 CY26 vs Q3 CY25 | Hydralyte LLC | US$ unless stated rsonal use only 54% 22% +71% LOWER MARKETING SPEND LOWER REVENUE REVENUE PER US$1 OF MARKETING US$373.5k → US$170.6k US$851.5k → US$665.2k US$2.28 → US$3.90 WHAT HAS CHANGED Marketing
Slide 9: Consolidated EBITDA losses reduced across Q3
Consolidated EBITDA losses reduced across Q3 Monthly comparison | A$ | unaudited consolidated management accounts rsonal use only MONTH Q3 2025 Q3 2026 REDUCTION IN LOSS EBITDA loss (A$) 370,679 318,064 July 2026 vs 2025 (370,679) (108,095) 70.8% 288,284 August 2026 vs 2025 (318,064) (27,546) 91.3%
Slide 10: US turnaround: what has changed?
US turnaround: what has changed? Board and management renewed; costs reduced and marketing refocused rsonal use only Board and management renewed in June 2026 Q3 operating expenses declined from US$746.4k (Q3 CY25) to US$313.9k (Q3 CY26), a 58% reduction (approximately US$144k per month) August LLC
Slide 11: Five operational priorities to improve earnings
Five operational priorities to improve earnings Protect margins. Keep products in stock. Scale sales without rebuilding the cost base. rsonal use only 1 Protect gross margin through product mix and disciplined pricing Tracked by: gross margin %, monthly 2 Improve availability of key SKUs and reduce
Slide 12: Board
Board The Board recommends all shareholders take up their entitlements (prospectus section 7.5) rsonal use only Nick Berry George Karafotias Nick Katiforis Non-Executive Chairman Non-Executive Director Non-Executive Director Portfolio Manager and director, PURE Previous director and manager of Finan
Slide 13: The rights issue: key terms
The rights issue: key terms Issue price A$0.004: 33.3% premium to last sale A$0.003 on 22 October 2026; free-attaching New Options included rsonal use only 2 for 3 A$0.004 ~A$1.435m 2 New Shares for every 3 existing Price per new share Maximum gross proceeds shares held • 1 free-attaching New Option
Slide 14: Offer timetable and eligibility
Offer timetable and eligibility Refer to the prospectus for the definitive offer terms rsonal use only 28 Oct 2026 2 Nov 2026 11 Nov 2026 16 Nov 2026 7 Dec 2026 Record date Offer opened Extension notice deadline Offer closes 5:00pm Share Sale Facility opt-out, (noon Sydney) Melbourne time 5:00pm Mel
Slide 15: Rights issue: use of funds
Rights issue: use of funds Up to A$1.277m for working capital at full subscription. The offer is not underwritten and has no minimum. rsonal use only Working capital by subscription level (A$m) Subscription Gross proceeds Offer costs Working capital A$1.28m 100% A$1,434,635 A$157,395 A$1,277,240 A$0
Slide 16: Post-rights issue capital structure
Post-rights issue capital structure — assuming full subscription Security Before offer Offer securities After offer rsonal use only Ordinary shares 537,988,485 358,658,990 896,647,475 Existing options 88,469,890 – 88,469,890 New Options – 179,329,495 179,329,495 Broker Options – 71,731,798 71,731,79
Slide 17: Summary: early improvements and material execution risks
Summary: early improvements and material execution risks July–August LLC improvement was followed by weaker September trading; group remains loss-making rsonal use only Early improvements Material risks • Q3 revenue fell 22% 85% Hydralyte LLC Q3 operating loss reduced year on year • Q3 gross margin
Slide 18: Investor next steps
Investor next steps Review the prospectus and consider the entitlement offer rsonal use only Offer closes 5:00pm Melbourne time, 16 November 2026, unless varied 1 2 3 Read the prospectus in full, Check your personalised Apply online via Automic Registry; including the risk factors Entitlement and Ac
The Hydration Pharmaceuticals Company — Investor Presentation (November 2026) on 6ix